Trial Profile
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Seasonal allergic rhinitis; Tree pollen hypersensitivity
- Focus Pharmacodynamics
- 08 Dec 2011 New trial record